UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation or organization) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (
________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
none |
| not applicable |
| not applicable |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Director
On October 19, 2022, Dr. Andrew Salzman submitted to the Board of Directors (the “Board”) of the Company, a notice of resignation from his position as a director of the Company, with such resignation to be effective immediately. The Board accepted the resignation of Dr. Salzman on October 19, 2022. The resignation of Dr. Salzman did not result from any disagreement with the Board. Dr. Salzman will remain the Company’s Chief Science Officer.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Innovation1 Biotech Inc. |
| |
|
|
|
|
Date: October 25, 2022 | By: | /s/ Jeffrey J. Kraws |
|
|
| Jeffrey J. Kraws Chief Executive Officer |
|
3 |
Cover |
Oct. 19, 2022 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | INNOVATION1 BIOTECH INC. |
Entity Central Index Key | 0001629205 |
Document Type | 8-K |
Amendment Flag | false |
Entity Emerging Growth Company | false |
Document Period End Date | Oct. 19, 2022 |
Entity Incorporation State Country Code | NV |
Entity File Number | 000-55852 |
Entity Tax Identification Number | 82-2275255 |
Entity Address Address Line 1 | 40 Wall Street |
Entity Address Address Line 2 | Suite 2701 |
Entity Address City Or Town | New York |
Entity Address State Or Province | NY |
Entity Address Postal Zip Code | 10005 |
City Area Code | 646 |
Local Phone Number | 380-1923 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
)C4(=0!VMOD.*>-A6-7MGO9O\=VFM!JG;0BE3Y42 (]R_V$-^K^J_[57.^:B$ZV8R^97[/@O-KT"YD1@'">D0F &C
M+-5"D..X"MQ+&M1#GXW>LG$JD9%NH?5